Litcius/Paper detail

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial

Alan Pollack, Theodore Karrison, Alexander G. Balogh, Leonard G. Gomella, Daniel A. Low, Deborah Watkins Bruner, Jeffrey S. Wefel, André‐Guy Martin, Jeff M. Michalski, Steve Angyalfi, Himanshu Lukka, Sergio Faria, George Rodrigues, Marie-Claude Beauchemin, R. Jeffrey Lee, Samantha A. Seaward, Aaron M. Allen, Drew C. Monitto, Wendy Seiferheld, Oliver Sartor, Felix Feng, Howard M. Sandler

2022The Lancet253 citationsDOIOpen Access PDF

Topics & Concepts

MedicineProstatectomyAndrogen deprivation therapyProstate cancerRadiation therapyUrologyLymphadenectomyClinical endpointProstate-specific antigenHazard ratioLymph nodeOncologyRandomized controlled trialInternal medicineCancerConfidence intervalProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchInflammatory Biomarkers in Disease Prognosis
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial | Litcius